Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Hepatitis

  Free Subscription


Articles published in J Med Virol

Retrieve available abstracts of 168 articles:
HTML format
Text format



Single Articles


    November 2017
  1. ISHIGAMI M, Hayashi K, Honda T, Kuzuya T, et al
    Daclatasvir and asunaprevir treatment in patients infected by genotype 1b of hepatitis C virus with no or subtle resistant associated substitutions (RAS) in NS5A-Y93.
    J Med Virol. 2017 Nov 7. doi: 10.1002/jmv.24978.
    PubMed     Text format     Abstract available


  2. SU S, Fairley CK, Sasadeusz J, He J, et al
    HBV, HCV, and HBV/HCV co-infection among HIV-positive patients in Hunan province, China: regimen selection, hepatotoxicity, and antiretroviral therapy outcome.
    J Med Virol. 2017 Nov 1. doi: 10.1002/jmv.24988.
    PubMed     Text format     Abstract available


    October 2017
  3. KIM DY, Lee HW, Song JE, Kim BK, et al
    Switching from Tenofovir and Nucleoside Analogue Therapy to Tenofovir Monotherapy in Virologically Suppressed Chronic Hepatitis B Patients with Antiviral Resistance.
    J Med Virol. 2017 Oct 27. doi: 10.1002/jmv.24986.
    PubMed     Text format     Abstract available


  4. MEZGEBO TA, Niguse S, Kahsay AG, Hailekiros H, et al
    HEPATITIS B VIRUS INFECTION AND ASSOCIATED RISK FACTORS AMONG PREGNANT WOMEN ATTENDING ANTENATAL CARE IN HEALTH FACILITIES OF TIGRAY, NORTHERN ETHIOPIA.
    J Med Virol. 2017 Oct 27. doi: 10.1002/jmv.24987.
    PubMed     Text format     Abstract available


  5. GEWAID H, Mesalam AA, Ibrahim AA, Abdel Shafy DN, et al
    Establishment of a platform for molecular and immunological characterization of the RNA-dependent-RNA-polymerase NS5B of an Egyptian HCV isolate.
    J Med Virol. 2017 Oct 24. doi: 10.1002/jmv.24977.
    PubMed     Text format     Abstract available


  6. SILVA RAD, de Souza Todao J, Kamitani FL, Benedito Silva AE, et al
    MOLECULAR CHARACTERIZATION OF HEPATITIS C VIRUS IN END-STAGE RENAL DISEASE PATIENTS UNDER HEMODIALYSIS.
    J Med Virol. 2017 Oct 24. doi: 10.1002/jmv.24976.
    PubMed     Text format     Abstract available


  7. JAVAN B, Reza Kalani M, Shahbazi M
    Interleukin-1 Gene Cluster Haplotype Analysis in the Chronic Outcome Prediction of the Hepatitis B Virus Infection.
    J Med Virol. 2017 Oct 11. doi: 10.1002/jmv.24972.
    PubMed     Text format     Abstract available


  8. AL-RADDADI RM, Dashash NA, Alghamdi HA, Al-Raddadi ZM, et al
    Hepatitis C virus infection in Jeddah City, Saudi Arabia: Seroprevalence and knowledge.
    J Med Virol. 2017 Oct 11. doi: 10.1002/jmv.24973.
    PubMed     Text format     Abstract available


  9. CARRASCO I, Arias A, Benitez-Gutierrez L, Lledo G, et al
    Baseline NS5A Resistance Associated Substitutions May Impair DAA Response in Real-World Hepatitis C Patients.
    J Med Virol. 2017 Oct 9. doi: 10.1002/jmv.24971.
    PubMed     Text format     Abstract available


    September 2017
  10. RAHMAN M, Hossain ME, Afrad MH, Hasan R, et al
    Hepatitis C Virus infections among clients attending an HIV testing and counseling center in Dhaka, Bangladesh.
    J Med Virol. 2017 Sep 28. doi: 10.1002/jmv.24955.
    PubMed     Text format     Abstract available


  11. CIANCIO A, Bosio R, Bo S, Pellegrini M, et al
    SIGNIFICANT IMPROVEMENT OF GLYCAEMIC CONTROL IN DIABETIC PATIENTS WITH HCV INFECTION RESPONDING TO DIRECT-ACTING ANTIVIRAL AGENTS.
    J Med Virol. 2017 Sep 28. doi: 10.1002/jmv.24954.
    PubMed     Text format     Abstract available


  12. ALVARADO-ESQUIVEL C, Sanchez-Anguiano LF, Hernandez-Tinoco J, Alvarado-Felix AO, et al
    Seroepidemiology of hepatitis E virus infection in pigs in Durango State, Mexico.
    J Med Virol. 2017 Sep 15. doi: 10.1002/jmv.24951.
    PubMed     Text format     Abstract available


  13. OGASAWARA N, Kobayashi M, Akuta N, Kominami Y, et al
    Serial changes in liver stiffness and controlled attenuation parameter following direct-acting antiviral therapy against hepatitis C virus genotype 1b.
    J Med Virol. 2017 Sep 14. doi: 10.1002/jmv.24950.
    PubMed     Text format     Abstract available


  14. AHMED AM, Doheim MF, Mattar OM, Sherif NA, et al
    Beclabuvir in combination with asunaprevir and daclatasvir for hepatitis C virus genotype 1 infection: A systematic review and meta-analysis.
    J Med Virol. 2017 Sep 11. doi: 10.1002/jmv.24947.
    PubMed     Text format     Abstract available


  15. SCHULZ TR, Edwards R, Thurnheer MC, Yuen L, et al
    Hepatitis B amongst Immigrants from Myanmar: Genotypes and their Clinical Relevance.
    J Med Virol. 2017 Sep 8. doi: 10.1002/jmv.24939.
    PubMed     Text format     Abstract available


  16. CAVARETTO LDSP, Motta-Castro ARC, Teles SA, de Souza FQ, et al
    Epidemiological and molecular analysis of hepatitis B virus infection in manicurists in Central Brazil.
    J Med Virol. 2017 Sep 8. doi: 10.1002/jmv.24940.
    PubMed     Text format     Abstract available


  17. ZHANG K, Liu Y, Chen R, Li Q, et al
    Antigenicity reduction contributes mostly to poor detectability of HBsAg by hepatitis B virus (HBV) S-gene mutants isolated from individuals with occult HBV infection.
    J Med Virol. 2017 Sep 6. doi: 10.1002/jmv.24936.
    PubMed     Text format     Abstract available


    August 2017
  18. MA X, Sun D, Li C, Ying J, et al
    Chronic hepatitis B virus infection and preterm labor(birth) in pregnant women-An updated systematic review and meta-analysis.
    J Med Virol. 2017 Aug 29. doi: 10.1002/jmv.24927.
    PubMed     Text format     Abstract available


  19. DEHGHANI-DEHEJ F, Sarvari J, Esghaei M, Hosseini SY, et al
    Presence of Different Hepatitis C Virus Genotypes in Plasma and Peripheral Blood Mononuclear Cell Samples of Iranian Patients with HIV Infection.
    J Med Virol. 2017 Aug 28. doi: 10.1002/jmv.24925.
    PubMed     Text format     Abstract available


  20. SHEPHERD SJ, McDonald SA, Palmateer NE, Gunson RN, et al
    HCV avidity as a tool for detection of recent HCV infection: sensitivity depends on HCV genotype.
    J Med Virol. 2017 Aug 26. doi: 10.1002/jmv.24919.
    PubMed     Text format     Abstract available


  21. SCHNELL G, Tripathi R, Krishnan P, Beyer J, et al
    Resistance Characterization of Hepatitis C Virus Genotype 2 from Japanese Patients Treated with Ombitasvir and Paritaprevir/Ritonavir.
    J Med Virol. 2017 Aug 26. doi: 10.1002/jmv.24923.
    PubMed     Text format     Abstract available


  22. MAHMUD S, Kanaani ZA, Chemaitelly H, Chaabna K, et al
    Hepatitis C Virus Genotypes in the Middle East and North Africa: Distribution, Diversity, and Patterns.
    J Med Virol. 2017 Aug 26. doi: 10.1002/jmv.24921.
    PubMed     Text format     Abstract available


  23. ZHAO C, Geng Y, Huang W, Ma H, et al
    Valuable Antibody Detection Method for Classifying Hepatitis E Virus Genotypes.
    J Med Virol. 2017 Aug 17. doi: 10.1002/jmv.24915.
    PubMed     Text format     Abstract available


  24. YANG T, Chen Q, Li D, Wang T, et al
    High prevalence of syphilis, HBV and HCV co-infection, and low rate of effective vaccination against hepatitis B in HIV-infected patients in West China hospital.
    J Med Virol. 2017 Aug 9. doi: 10.1002/jmv.24912.
    PubMed     Text format     Abstract available


  25. TSATSRALT-OD B, Primadharsini PP, Nishizawa T, Ohnishi H, et al
    Distinct changing profiles of hepatitis A and E virus infection among patients with acute hepatitis in Mongolia: The first report of the full genome sequence of a novel genotype 1 hepatitis E virus strain.
    J Med Virol. 2017 Aug 4. doi: 10.1002/jmv.24907.
    PubMed     Text format     Abstract available


    July 2017
  26. WEHMEYER MH, Ingiliz P, Christensen S, Hueppe D, et al
    Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: results from the multicenter German hepatitis C cohort (GECCO-03).
    J Med Virol. 2017 Jul 15. doi: 10.1002/jmv.24903.
    PubMed     Text format     Abstract available


  27. LISBOA NETO G, M Malta F, Gomes-Gouvea MS, F Noble C, et al
    CHARACTERIZATION OF CLINICAL PREDICTORS OF NATURALLY OCCURRING NS3/NS4A PROTEASE POLYMORPHISM IN GENOTYPE 1 HEPATITIS C VIRUS MONO AND HIV CO-INFECTED PATIENTS.
    J Med Virol. 2017 Jul 12. doi: 10.1002/jmv.24900.
    PubMed     Text format     Abstract available


  28. LU J, Xiang X, Cao Z, Wang W, et al
    Younger trend of cirrhosis incidence in genotype 3 HCV infected patients in Eastern China.
    J Med Virol. 2017 Jul 3. doi: 10.1002/jmv.24894.
    PubMed     Text format     Abstract available


  29. OSAWA M, Akuta N, Suzuki F, Fujiyama S, et al
    Prognosis and predictors of hepatocellular carcinoma in elderly patients infected with hepatitis B virus.
    J Med Virol. 2017 Jul 1. doi: 10.1002/jmv.24890.
    PubMed     Text format     Abstract available


    June 2017
  30. CHEN T, Xun Z, Lin J, Fu Y, et al
    Association between mitochondrial DNA content and baseline serum levels of HBsAg in chronic hepatitis B infection.
    J Med Virol. 2017 Jun 28. doi: 10.1002/jmv.24886.
    PubMed     Text format     Abstract available


  31. KAN H, Imamura M, Kawakami Y, Daijo K, et al
    Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients.
    J Med Virol. 2017 Jun 28. doi: 10.1002/jmv.24885.
    PubMed     Text format     Abstract available


  32. COSTANTINO A, Coppola N, Spada E, Bruni R, et al
    Hepatitis A virus strains circulating during 1997-2015 in Campania, a Southern Italy region with periodic outbreaks.
    J Med Virol. 2017 Jun 16. doi: 10.1002/jmv.24880.
    PubMed     Text format     Abstract available


  33. ADEYEMI OO, Herod MR, Oladiji F, Fakunle YM, et al
    A multi-template multiplex PCR assay for hepatitis B virus and human beta-globin.
    J Med Virol. 2017 Jun 15. doi: 10.1002/jmv.24877.
    PubMed     Text format     Abstract available


  34. AHN HS, Park BJ, Han SH, Kim YH, et al
    Prevalence and Genetic Features of Rabbit Hepatitis E Virus in Korea.
    J Med Virol. 2017 Jun 15. doi: 10.1002/jmv.24875.
    PubMed     Text format     Abstract available


  35. CAI Y, Qin SY, Qian A, Xu P, et al
    Seroprevalence and risk factors of hepatitis E virus infection among the Korean, Manchu, Mongol and Han ethnic groups in eastern and northeastern China.
    J Med Virol. 2017 Jun 3. doi: 10.1002/jmv.24871.
    PubMed     Text format     Abstract available


  36. SAGNELLI C, Ciccozzi M, Coppola N, Minichini C, et al
    Molecular diversity in irregular or refugee immigrant patients with HBV-genotype-E infection living in the metropolitan area of Naples.
    J Med Virol. 2017;89:1015-1024.
    PubMed     Text format     Abstract available


  37. MOBARAK L, Omran D, Nabeel MM, Zakaria Z, et al
    Fibro markers for prediction of hepatocellular carcinoma in Egyptian patients with chronic liver disease.
    J Med Virol. 2017;89:1062-1068.
    PubMed     Text format     Abstract available


    May 2017
  38. SHI X, Jiao B, Chen Y, Li S, et al
    MxA Is A Positive Regulator of Type I IFN Signaling in HCV Infection.
    J Med Virol. 2017 May 31. doi: 10.1002/jmv.24867.
    PubMed     Text format     Abstract available


  39. HUANG X, Ma C, Zhang Q, Shi Q, et al
    Impact of "a" Determinant Mutations on Detection of Hepatitis B Surface Antigen (HBsAg) in HBV Strains from Chinese Patients with Occult Hepatitis B.
    J Med Virol. 2017 May 17. doi: 10.1002/jmv.24859.
    PubMed     Text format     Abstract available


  40. DOS SANTOS MIMA, Rugiere SP, Stocker A, Schinoni MI, et al
    Mutations Associated With Drug Resistance and Prevalence of Vaccine Escape Mutations In Patients With Chronic Hepatitis B Infection.
    J Med Virol. 2017 May 13. doi: 10.1002/jmv.24853.
    PubMed     Text format     Abstract available


  41. KAR P, Kumar D, Gumma PK, Chowdhury SJ, et al
    Down regulation of TRIF, TLR3 and MAVS in HCV infected liver correlates with the outcome of infection.
    J Med Virol. 2017 May 8. doi: 10.1002/jmv.24849.
    PubMed     Text format     Abstract available


  42. HUDSON B, Walker AJ, Irving WL
    Comorbidities and medications of patients with chronic hepatitis C under specialist care in the UK.
    J Med Virol. 2017 May 8. doi: 10.1002/jmv.24848.
    PubMed     Text format     Abstract available


  43. RAZIKY ME, Zayed NA, Baki AA, Mansour SA, et al
    ITPA Gene polymorphism (94C>A) Effects on Ribavirin-Induced Anemia during Therapy in Egyptian Patients with Chronic Hepatitis C.
    J Med Virol. 2017 May 8. doi: 10.1002/jmv.24844.
    PubMed     Text format     Abstract available


  44. SCOGNAMIGLIO P, Piselli P, Fusco M, Pisanti FA, et al
    DECLINING UNAWARENESS OF HCV-INFECTION PARALLEL TO DECLINING PREVALENCE IN SOUTHERN ITALY.
    J Med Virol. 2017 May 2. doi: 10.1002/jmv.24840.
    PubMed     Text format     Abstract available


  45. TRIPODI G, Larsson SB, Norkrans G, Lindh M, et al
    Smaller reduction of hepatitis B virus DNA in liver tissue than in serum in patients losing HBeAg.
    J Med Virol. 2017 May 2. doi: 10.1002/jmv.24841.
    PubMed     Text format     Abstract available


  46. LONG F, Yu W, Yang C, Wang J, et al
    High prevalence of Hepatitis E virus infection in goats.
    J Med Virol. 2017 May 2. doi: 10.1002/jmv.24843.
    PubMed     Text format     Abstract available


    April 2017
  47. SHINDANO TA, Horsmans Y, Kabamba BM
    GENETIC AND PHYLOGENIC CHARACTERISATION OF HEPATITIS B VIRUS IN THE EASTERN PART OF THE DEMOCRATIC REPUBLIC OF CONGO.
    J Med Virol. 2017 Apr 29. doi: 10.1002/jmv.24837.
    PubMed     Text format     Abstract available


  48. CHAN MC, Cheng FW, Sze KH, Wong AH, et al
    Hepatitis B infection acquired after haematopioetic stem cell transplant through horizontal mode.
    J Med Virol. 2017 Apr 29. doi: 10.1002/jmv.24835.
    PubMed     Text format     Abstract available


  49. DE PASCHALE M, Manco MT, Arpino O, Ricucci V, et al
    Threshold value of LIAISON XL anti-HCV screening assay predicting positive immunoblotting results.
    J Med Virol. 2017 Apr 12. doi: 10.1002/jmv.24831.
    PubMed     Text format     Abstract available


  50. WANG J, Zhang H, Zhang Y, Jiang D, et al
    Influences on viral replication and sensitivity to GLS4, a HAP compound, of naturally occurring T109/V124 mutations in hepatitis B virus core protein.
    J Med Virol. 2017 Apr 12. doi: 10.1002/jmv.24830.
    PubMed     Text format     Abstract available


  51. JIAO X, Fan Z, Chen H, He P, et al
    Serum and exosomal miR-122 and miR-199a as a biomarker to predict therapeutic efficacy of hepatitis C patients.
    J Med Virol. 2017 Apr 12. doi: 10.1002/jmv.24829.
    PubMed     Text format     Abstract available


  52. EL-MOWAFY M, Elgaml A, El-Mesery M, Elegezy M, et al
    Molecular analysis of Hepatitis B virus sub-genotypes and incidence of preS1/preS2 region mutations in HBV-infected Egyptian patients from Mansoura.
    J Med Virol. 2017 Apr 8. doi: 10.1002/jmv.24828.
    PubMed     Text format     Abstract available


    March 2017
  53. MENDIZABAL M, Haddad L, Gallardo PE, Ferrada A, et al
    Ombitasvir/paritaprevir/ritonavir/dasabuvir +/- ribavirin is safe and effective in HCV infected patients in a real-life cohort from Latin America.
    J Med Virol. 2017 Mar 29. doi: 10.1002/jmv.24816.
    PubMed     Text format     Abstract available


  54. KHALIFA RH, Labib DA, Kamel MA, Shahin RM, et al
    Role of ApoB-516C/T promoter gene polymorphism in the risk of Hepatitis C virus infection in Egyptian patients and in gender susceptibility.
    J Med Virol. 2017 Mar 29. doi: 10.1002/jmv.24815.
    PubMed     Text format     Abstract available


  55. HIRAMATSU K, Matsuda H, Nemoto T, Nosaka T, et al
    Identification of novel variants in HLA class II region related to HLA DPB1 expression and disease progression in patients with chronic hepatitis C.
    J Med Virol. 2017 Mar 22. doi: 10.1002/jmv.24814.
    PubMed     Text format     Abstract available


  56. EIJSVOOGEL NB, Hollegien MI, Bok LA, Derksen-Lubsen A, et al
    Declining antibody levels after hepatitis B vaccination in Down syndrome: a need for booster vaccination?
    J Med Virol. 2017 Mar 21. doi: 10.1002/jmv.24813.
    PubMed     Text format     Abstract available


  57. JONES M, Cunningham ME, Wing P, DeSilva S, et al
    SB 9200, a novel agonist of innate immunity, shows potent antiviral activity against resistant HCV variants.
    J Med Virol. 2017 Mar 17. doi: 10.1002/jmv.24809.
    PubMed     Text format     Abstract available


  58. CICCOZZI M, Chaouch H, Lo Presti A, Taffon S, et al
    Evolutionary dynamics of HBV-D7 subgenotype in Tunisia.
    J Med Virol. 2017;89:469-475.
    PubMed     Text format     Abstract available


  59. ZHANG Y, Wang L, Zeng H, Gong W, et al
    Development and validation of a new serum standard for the measurement of anti-HEV antibodies in animals.
    J Med Virol. 2017;89:497-501.
    PubMed     Text format     Abstract available


    February 2017
  60. YANG Y, Du D, Jin L, Tian Z, et al
    A molecular epidemiology study investigating familial clustering of hepatitis B virus infection in families with unfavorable prognoses in Northwest China.
    J Med Virol. 2017 Feb 15. doi: 10.1002/jmv.24783.
    PubMed     Text format     Abstract available


  61. FU X, Chen J, Chen H, Lin J, et al
    Mutation in the S gene of hepatitis B virus and anti-HBs subtype-nonspecificity contributed to the coexistence of HBsAg and anti-HBs in patients with chronic hepatitis B virus infection.
    J Med Virol. 2017 Feb 15. doi: 10.1002/jmv.24782.
    PubMed     Text format     Abstract available


  62. FLORES GL, Cruz HM, Marques VA, Villela-Nogueira CA, et al
    Performance of anti-HCV testing in dried blood spots and saliva according to HIV status.
    J Med Virol. 2017 Feb 6. doi: 10.1002/jmv.24777.
    PubMed     Text format     Abstract available


  63. WATANABE T, Tokumoto Y, Joko K, Michitaka K, et al
    Predictors of treatment efficacy and ALT non-normalization with sofosbuvir/ribavirin therapy for patients with hepatitis C virus genotype 2.
    J Med Virol. 2017 Feb 6. doi: 10.1002/jmv.24776.
    PubMed     Text format     Abstract available


    January 2017
  64. HUNDIE GB, Raj VS, Gebre Michael D, Haagmans BL, et al
    Seroepidemiology of hepatitis B and C virus infections among blood donors in Ethiopia.
    J Med Virol. 2017 Jan 25. doi: 10.1002/jmv.24770.
    PubMed     Text format     Abstract available


  65. AKUTA N, Sezaki H, Suzuki F, Fujiyama S, et al
    Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens.
    J Med Virol. 2017 Jan 12. doi: 10.1002/jmv.24767.
    PubMed     Text format     Abstract available


  66. GRANDAL M, Pernas B, Marino A, Alvarez H, et al
    Characterization of chronic HCV infection in Northwest Spain: Impact of the treatment strategic plan of the Spanish National Health Service on HCV cure.
    J Med Virol. 2017 Jan 12. doi: 10.1002/jmv.24766.
    PubMed     Text format     Abstract available


    December 2016
  67. MURAKAWA M, Asahina Y, Kawai-Kitahata F, Nakagawa M, et al
    Hepatic IFNL4 expression is associated with non-response to interferon-based therapy through the regulation of basal interferon-stimulated gene expression in chronic hepatitis C patients.
    J Med Virol. 2016 Dec 30. doi: 10.1002/jmv.24763.
    PubMed     Text format     Abstract available


  68. LIU X, Zhang L, Wu XP, Zhu XL, et al
    Polymorphisms in IRG1 gene associated with immune responses to hepatitis B vaccination in a Chinese Han population and function to restrain the HBV life cycle.
    J Med Virol. 2016 Dec 22. doi: 10.1002/jmv.24756.
    PubMed     Text format     Abstract available


  69. WANG L, Chen W, WenXi, Feng J, et al
    The utility of enzyme-linked immunosorbent assays to test core antigen in the diagnosis and antiviral therapy management of hepatitis C virus infections.
    J Med Virol. 2016 Dec 13. doi: 10.1002/jmv.24754.
    PubMed     Text format     Abstract available


  70. ZHAO N, Liu J, Sun D
    Detection of HCV genotypes 1b and 2a by a reverse transcription loop-mediated isothermal amplification assay.
    J Med Virol. 2016 Dec 9. doi: 10.1002/jmv.24747.
    PubMed     Text format     Abstract available


  71. MADEDDU G, Ortu S, Garrucciu G, Maida I, et al
    DNMT1 modulation in Chronic Hepatitis B patients and hypothetic influence on Mitochondrial DNA methylation status during long-term Nucleo(t)side Analogues Therapy.
    J Med Virol. 2016 Dec 6. doi: 10.1002/jmv.24742.
    PubMed     Text format     Abstract available


  72. KODANI M, Ahmed N, Tejada-Strop A, Poe A, et al
    Variability in the performance characteristics of IgG anti-HEV assays and its impact on reliability of seroprevalence rates of hepatitis E.
    J Med Virol. 2016 Dec 6. doi: 10.1002/jmv.24741.
    PubMed     Text format     Abstract available


  73. MIURA M, Inoue J, Tsuruoka M, Nishizawa T, et al
    Full-length genomic sequence analysis of new subtype 3k hepatitis E virus isolates with 99.97% nucleotide identity obtained from two consecutive acute hepatitis patients in a city in northeast Japan.
    J Med Virol. 2016 Dec 6. doi: 10.1002/jmv.24743.
    PubMed     Text format     Abstract available


  74. NGOC NB, Okuno Y, Ajiro M, Iida K, et al
    Retinoid derivative Tp80 exhibits anti-hepatitis C virus activity through restoration of GI-GPx expression.
    J Med Virol. 2016 Dec 6. doi: 10.1002/jmv.24739.
    PubMed     Text format     Abstract available


    November 2016
  75. ELFIKY AA, Mahdy SM, Elshemey WM
    Quantitative structure-activity relationship and molecular docking revealed a potency of anti-hepatitis C virus drugs against human corona viruses.
    J Med Virol. 2016 Nov 19. doi: 10.1002/jmv.24736.
    PubMed     Text format     Abstract available


  76. THURNHEER MC, Edwards R, Schulz TR, Yuen L, et al
    Genotypic profiles of Hepatitis B in African immigrants and their clinical relevance.
    J Med Virol. 2016 Nov 11. doi: 10.1002/jmv.24732.
    PubMed     Text format     Abstract available


  77. SALEMI JL, Spooner KK, Mejia de Grubb MC, Aggarwal A, et al
    National trends of hepatitis B and C during pregnancy across sociodemographic, behavioral, and clinical factors, United States, 1998-2011.
    J Med Virol. 2016 Nov 2. doi: 10.1002/jmv.24725.
    PubMed     Text format     Abstract available


  78. BODEAU S, Lemouel JP, Diouf M, Duverlie G, et al
    Hemoglobin during ribavirin-based HCV therapy is closely related to circulating levels of DHEA.
    J Med Virol. 2016 Nov 2. doi: 10.1002/jmv.24726.
    PubMed     Text format     Abstract available


    October 2016
  79. KATAKI K, Borthakur P, Kumari N, Deka M, et al
    Association of mRNA expression of Toll like receptor 2 and 3 with hepatitis B viral load in chronic hepatitis, cirrhosis and hepatocellular carcinoma.
    J Med Virol. 2016 Oct 21. doi: 10.1002/jmv.24719.
    PubMed     Text format     Abstract available


  80. KANG SH, Kang K, Yeon JE, Lee YS, et al
    Antiviral response is not sustained after cessation of lamivudine treatment in chronic hepatitis B patients: A 10-year follow-up study.
    J Med Virol. 2016 Oct 21. doi: 10.1002/jmv.24715.
    PubMed     Text format     Abstract available


  81. HUMAYED SM, El-Mekki AA, Mahfouz AA
    Hepatitis C virus infection in south-western Saudi Arabia: Are we still in the plateau phase?
    J Med Virol. 2016 Oct 13. doi: 10.1002/jmv.24712.
    PubMed     Text format     Abstract available


  82. KUMAR R, Testoni B, Fresquet J, Lim TK, et al
    Development of hepatocellular carcinoma in chronic hepatitis B patients with advanced fibrosis is independent of viral genotype.
    J Med Virol. 2016 Oct 6. doi: 10.1002/jmv.24707.
    PubMed     Text format     Abstract available


  83. CLAUS M, Kimbel R, Schone K, Letzel S, et al
    Seroepidemiology of hepatitis A and B and vaccination status in staff at German schools for the handicapped.
    J Med Virol. 2016 Oct 3. doi: 10.1002/jmv.24699.
    PubMed     Text format     Abstract available


    September 2016
  84. KANG YH, Cong W, Zhang XY, Wang CF, et al
    Hepatitis E virus seroprevalence among farmers, veterinarians and control subjects in Jilin province, Shandong province and Inner Mongolia Autonomous Region, China.
    J Med Virol. 2016 Sep 24. doi: 10.1002/jmv.24693.
    PubMed     Text format     Abstract available


  85. TSUKUDA Y, Suda G, Tsunematsu S, Ito J, et al
    Anti-adipogenic and antiviral effects of L-carnitine on hepatitis C virus infection.
    J Med Virol. 2016 Sep 24. doi: 10.1002/jmv.24692.
    PubMed     Text format     Abstract available


  86. ROUABHIA S, Chaabna K
    Hepatitis C infection in eastern Algeria: Between statistics and reality.
    J Med Virol. 2016 Sep 14. doi: 10.1002/jmv.24686.
    PubMed     Text format     Abstract available


  87. ELFIKY AA
    Zika viral polymerase inhibition using anti-HCV drugs both in market and under clinical trials.
    J Med Virol. 2016 Sep 7. doi: 10.1002/jmv.24678.
    PubMed     Text format     Abstract available


  88. NAKAMURA Y, Imamura M, Kawakami Y, Teraoka Y, et al
    Efficacy and safety of daclatasvir plus asunaprevir therapy for chronic hepatitis C patients with renal dysfunction.
    J Med Virol. 2016 Sep 7. doi: 10.1002/jmv.24679.
    PubMed     Text format     Abstract available


  89. JOGEDA EL, Huik K, Pauskar M, Kallas E, et al
    The prevalence and genotypes of GBV-C and its associations with HIV infection among persons who inject drugs in Eastern Europe.
    J Med Virol. 2016 Sep 7. doi: 10.1002/jmv.24683.
    PubMed     Text format     Abstract available


  90. EL-EKIABY NM, Mekky RY, Riad SE, Elhelw DS, et al
    miR-148a and miR-30a limit HCV-dependent suppression of the lipid droplet protein, ADRP, in HCV infected cell models.
    J Med Virol. 2016 Sep 3. doi: 10.1002/jmv.24677.
    PubMed     Text format     Abstract available


    August 2016
  91. CELLA E, Ceccarelli G, Vita S, Lai A, et al
    First epidemiological and phylogenetic analysis of hepatitis B virus infection in migrants from Mali.
    J Med Virol. 2016 Aug 30. doi: 10.1002/jmv.24671.
    PubMed     Text format     Abstract available


  92. WU S, Yan P, Yang T, Wang Z, et al
    Epidemiological profile and risk factors of HIV and HBV/HCV co-infection in Fujian Province, southeastern China.
    J Med Virol. 2016 Aug 23. doi: 10.1002/jmv.24666.
    PubMed     Text format     Abstract available


  93. MARCIANO S, Haddad L, Plazzotta F, Mauro E, et al
    Implementation of the ECHO(R) telementoring model for the treatment of patients with hepatitis C.
    J Med Virol. 2016 Aug 23. doi: 10.1002/jmv.24668.
    PubMed     Text format     Abstract available


  94. KOBAYASHI M, Suzuki F, Fujiyama S, Kawamura Y, et al
    Sustained virologic response by direct anti-viral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection.
    J Med Virol. 2016 Aug 17. doi: 10.1002/jmv.24663.
    PubMed     Text format     Abstract available


  95. HAYES CN, Chayama K
    Interferon stimulated genes and innate immune activation following infection with hepatitis B and C viruses.
    J Med Virol. 2016 Aug 10. doi: 10.1002/jmv.24659.
    PubMed     Text format     Abstract available


  96. SONG G, Yang R, Rao H, Feng B, et al
    Serum HBV core related antigen is a good predictor for spontaneous HBeAg seroconversion in chronic hepatitis B patients.
    J Med Virol. 2016 Aug 9. doi: 10.1002/jmv.24657.
    PubMed     Text format     Abstract available


  97. YONG HAO G, Da Xing F, Jin X, Xiu Hong F, et al
    The prevalence of hepatitis B infection in central China: An adult population-based serological survey of a large sample size.
    J Med Virol. 2016 Aug 9. doi: 10.1002/jmv.24649.
    PubMed     Text format     Abstract available


  98. ALBUQUERQUE IC, Sousa MT, Santos MD, Nunes JD, et al
    Mutation in the a-determinant of the S gene of the hepatitis B virus associated with concomitant HBsAg and anti-HBs in a population in northeastern Brazil.
    J Med Virol. 2016 Aug 2. doi: 10.1002/jmv.24653.
    PubMed     Text format     Abstract available


  99. YILMAZ B
    Fulminant hepatitis B as a result of reactivation in hematologic patient after rituximab therapy.
    J Med Virol. 2016;88:1289-90.
    PubMed     Text format    


    July 2016
  100. DE PASCHALE M, Manco MT, Belvisi L, Cagnin D, et al
    Evaluation of LIAISON(R) XL system for HBsAg, and anti-HCV and anti-HIV/Ag p24.
    J Med Virol. 2016 Jul 28. doi: 10.1002/jmv.24648.
    PubMed     Text format     Abstract available


  101. TSUNEMATSU S, Suda G, Yamasaki K, Kimura M, et al
    Hepatitis B virus X protein impairs alpha-interferon signaling via up-regulation of suppressor of cytokine signaling 3 and protein phosphatase 2A.
    J Med Virol. 2016 Jul 26. doi: 10.1002/jmv.24643.
    PubMed     Text format     Abstract available


  102. REBBANI K, Ababou M, Nadifi S, Kandil M, et al
    Myxovirus resistance 1 gene polymorphisms and outcomes of viral hepatitis B and C infections in Moroccan patients.
    J Med Virol. 2016 Jul 26. doi: 10.1002/jmv.24642.
    PubMed     Text format     Abstract available


  103. BAUDI I, Iijima S, Chin'ombe N, Mtapuri-Zinyowera S, et al
    Molecular epidemiology of co-infection with hepatitis B virus and human immunodeficiency virus (HIV) among adult patients in Harare, Zimbabwe.
    J Med Virol. 2016 Jul 26. doi: 10.1002/jmv.24641.
    PubMed     Text format     Abstract available


  104. HOULDSWORTH A
    Exploring the possibility of arthropod transmission of HCV.
    J Med Virol. 2016 Jul 22. doi: 10.1002/jmv.24638.
    PubMed     Text format     Abstract available


  105. MORISCO F, Loperto I, Stroffolini T, Lombardo FL, et al
    Prevalence and risk factors of HCV infection in a metropolitan area in Southern Italy: Tail of a cohort infected in past decades.
    J Med Virol. 2016 Jul 19. doi: 10.1002/jmv.24635.
    PubMed     Text format     Abstract available


  106. SADEGHI A, Shirvani-Dastgerdi E, Tacke F, Yagmur E, et al
    HBsAg mutations related to occult hepatitis B virus infection in HIV-positive patients result in a reduced secretion and conformational changes of HBsAg.
    J Med Virol. 2016 Jul 6. doi: 10.1002/jmv.24623.
    PubMed     Text format     Abstract available


  107. OLIVEIRA MP, Lemes PS, Matos MA, Del-Rios NH, et al
    Overt and occult hepatitis B virus infection among treatment-naive HIV-infected patients in Brazil.
    J Med Virol. 2016;88:1222-9.
    PubMed     Text format     Abstract available


    June 2016
  108. LEI JH, Tian Y, Luo HY, Chen Z, et al
    Guillain-Barre syndrome following acute co-super-infection of hepatitis E virus and cytomegalovirus in a chronic hepatitis B virus carrier.
    J Med Virol. 2016 Jun 30. doi: 10.1002/jmv.24620.
    PubMed     Text format     Abstract available


  109. AKUTA N, Sezaki H, Suzuki F, Fujiyama S, et al
    Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan.
    J Med Virol. 2016 Jun 30. doi: 10.1002/jmv.24617.
    PubMed     Text format     Abstract available


  110. KIM MN, Park JY, Ahn SH, Kim BK, et al
    Durability of the virological response after lamivudine discontinuation in lamivudine-resistant patients with a complete virological response after lamivudine and adefovir combination therapy.
    J Med Virol. 2016 Jun 30. doi: 10.1002/jmv.24616.
    PubMed     Text format     Abstract available


  111. IKEDA H, Watanabe T, Okuse C, Matsumoto N, et al
    Impact of resistance-associated variant dominancy on treatment in patients with HCV genotype 1b receiving daclatasvir/asunaprevir.
    J Med Virol. 2016 Jun 22. doi: 10.1002/jmv.24608.
    PubMed     Text format     Abstract available


  112. LIAO H, Li X, Liu Y, Xu Z, et al
    Intergenotype recombinant analysis of full-length hepatitis B virus genomes from 516 Chinese patients with different illness categories.
    J Med Virol. 2016 Jun 22. doi: 10.1002/jmv.24609.
    PubMed     Text format     Abstract available


  113. CHUAYPEN N, Sriprapun M, Praianantathavorn K, Payungporn S, et al
    Kinetics of serum HBsAg and intrahepatic cccDNA during pegylated interferon therapy in patients with HBeAg-positive and HBeAg-negative chronic hepatitis B.
    J Med Virol. 2016 Jun 16. doi: 10.1002/jmv.24601.
    PubMed     Text format     Abstract available


  114. BEGHIN JC, Ruelle J, Sokal E, Bachy A, et al
    Effectiveness of the South African expanded program of immunization against hepatitis B in children infected with human immunodeficiency virus-1 living in a resource-limited setting of Kwazulu-Natal.
    J Med Virol. 2016 Jun 13. doi: 10.1002/jmv.24598.
    PubMed     Text format     Abstract available


  115. LIN JW, Chang ML, Hsu CW, Chen YC, et al
    Acute exacerbation of hepatitis C in hepatocellular carcinoma patients receiving chemotherapy.
    J Med Virol. 2016 Jun 8. doi: 10.1002/jmv.24595.
    PubMed     Text format     Abstract available


  116. AKUTA N, Sezaki H, Suzuki F, Kawamura Y, et al
    Favorable efficacy of daclatasvir plus asunaprevir in treatment of elderly Japanese patients infected with HCV genotype 1b aged 70 and older.
    J Med Virol. 2016 Jun 3. doi: 10.1002/jmv.24592.
    PubMed     Text format     Abstract available


  117. CHUNG A, Jin B, Han KH, Ahn SH, et al
    Cell culture-adaptive mutations of NS5A affect replication of hepatitis C virus differentially depending on the viral genotypes.
    J Med Virol. 2016 Jun 2. doi: 10.1002/jmv.24591.
    PubMed     Text format     Abstract available


  118. CANDOTTI D, Diarra B, Bisseye C, Tao I, et al
    Molecular characterization of hepatitis B virus in blood donors from Burkina Faso: prevalence of quasi-subgenotype A3, genotype E and mixed infections.
    J Med Virol. 2016 Jun 2. doi: 10.1002/jmv.24589.
    PubMed     Text format     Abstract available


  119. DIRCHWOLF M, Marciano S, Mauro E, Ruf A, et al
    Clinical epidemiology of acute hepatitis C in South America.
    J Med Virol. 2016 Jun 2. doi: 10.1002/jmv.24588.
    PubMed     Text format     Abstract available


    May 2016
  120. TAJIMA K, NaotoTakahashi, Ishizawa K, Murai K, et al
    High prevalence of diffuse large B-cell lymphoma in occult hepatitis B virus-infected patients in the Tohoku district in Eastern Japan.
    J Med Virol. 2016 May 24. doi: 10.1002/jmv.24584.
    PubMed     Text format     Abstract available


  121. ANDRIAMANDIMBY SF, Presti AL, Lai A, Olive MM, et al
    Genetic diversity of hepatitis B virus (HBV) in Madagascar.
    J Med Virol. 2016 May 16. doi: 10.1002/jmv.24576.
    PubMed     Text format     Abstract available


  122. HELAL GK, Gad MA, Abd-Ellah MF, Eid MS, et al
    Hydroxychloroquine augments early virological response to pegylated interferon plus ribavirin in genotype-4 chronic hepatitis C patients.
    J Med Virol. 2016 May 16. doi: 10.1002/jmv.24575.
    PubMed     Text format     Abstract available


  123. ALBERTI A, Lacoin L, Morais E, Lefevre C, et al
    A literature review of the distribution of hepatitis C virus genotypes across Europe.
    J Med Virol. 2016 May 12. doi: 10.1002/jmv.24573.
    PubMed     Text format     Abstract available


  124. BANG BR, Elmasry S, Saito T
    Organ system view of the hepatic innate immunity in HCV infection.
    J Med Virol. 2016 May 6. doi: 10.1002/jmv.24569.
    PubMed     Text format     Abstract available


  125. MISHRA S, Borkakoti J, Kumar S, Kar P, et al
    Role of HEV antigen detection in HEV related acute viral hepatitis and acute liver failure.
    J Med Virol. 2016 May 5. doi: 10.1002/jmv.24567.
    PubMed     Text format     Abstract available


  126. GUEYE SB, Diop-Ndiaye H, Lo G, Mintsa S, et al
    HBV carriage in children born from HIV-seropositive mothers in Senegal: The need of birth-dose HBV vaccination.
    J Med Virol. 2016;88:815-9.
    PubMed     Text format     Abstract available


    April 2016
  127. WANG LS, D'Souza LS, Jacobson IM
    Hepatitis C- A clinical review.
    J Med Virol. 2016 Apr 20. doi: 10.1002/jmv.24554.
    PubMed     Text format     Abstract available


  128. TSANKOVA GS, Kostadinova T, Todorova TT
    Seroprevalence of hepatitis B among pregnant women in Varna Region, Bulgaria.
    J Med Virol. 2016 Apr 6. doi: 10.1002/jmv.24543.
    PubMed     Text format     Abstract available


  129. LIU L, Wang L, Xia J, Zhang Y, et al
    Mix-breeding with HEV-infected swine induced inapparent HEV infection in SPF rabbits.
    J Med Virol. 2016;88:681-5.
    PubMed     Text format     Abstract available


  130. VARGAS JI, Jensen D, Sarmiento V, Peirano F, et al
    Presence of anti-HBc is associated to high rates of HBV resolved infection and low threshold for Occult HBV Infection in HIV patients with negative HBsAg in Chile.
    J Med Virol. 2016;88:639-46.
    PubMed     Text format     Abstract available


    March 2016
  131. SILVA MC, Silva CA, Machado GU, Atta A, et al
    HCV/HTLV coinfection: Does HTLV-1 interfere in the natural history of HCV-related diseases?
    J Med Virol. 2016 Mar 30. doi: 10.1002/jmv.24538.
    PubMed     Text format     Abstract available


  132. PEDERSEN J, Lundbo LF, Krarup H, Bukh J, et al
    Neutralizing antibodies in patients with chronic hepatitis C and correlation to liver cirrhosis and estimated duration of infection.
    J Med Virol. 2016 Mar 29. doi: 10.1002/jmv.24537.
    PubMed     Text format     Abstract available


  133. CHAIWONG S, Sistayanarain A
    Characterization of partial NS5B region among hepatitis C virus genotype 6 subtypes isolated from thai blood donors.
    J Med Virol. 2016 Mar 27. doi: 10.1002/jmv.24536.
    PubMed     Text format     Abstract available


  134. BOGLIONE L, Cariti G, Di Perri G, D'Avolio A, et al
    Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B.
    J Med Virol. 2016 Mar 27. doi: 10.1002/jmv.24534.
    PubMed     Text format     Abstract available


  135. TAHATA Y, Hiramatsu N, Oze T, Urabe A, et al
    The impact of ribavirin dosage in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin combination therapy.
    J Med Virol. 2016 Mar 18. doi: 10.1002/jmv.24528.
    PubMed     Text format     Abstract available


  136. COPPOLA N, Minichini C, Starace M, Sagnelli C, et al
    Clinical impact of the hepatitis C virus mutations in the era of directly acting antivirals.
    J Med Virol. 2016 Mar 18. doi: 10.1002/jmv.24527.
    PubMed     Text format     Abstract available


  137. EL-GHITANY EM, Farghaly AG, Abdel Wahab MM, Farag S, et al
    Towards a simple risk assessment screening tool for HCV infection in Egypt.
    J Med Virol. 2016 Mar 11. doi: 10.1002/jmv.24520.
    PubMed     Text format     Abstract available


  138. GUSATTI CS, Costi C, de Medeiros RM, Halon ML, et al
    Association between cytokine gene polymorphisms and outcome of hepatitis B virus infection in southern Brazil.
    J Med Virol. 2016 Mar 9. doi: 10.1002/jmv.24518.
    PubMed     Text format     Abstract available


  139. AN J, Shim JH, Kim SO, Choi J, et al
    Comprehensive outcomes of on- and off-antiviral prophylaxis in hepatitis B patients undergoing cancer chemotherapy: A competing risks analysis.
    J Med Virol. 2016 Mar 4. doi: 10.1002/jmv.24512.
    PubMed     Text format     Abstract available


  140. WEN J, Song C, Liu J, Chen J, et al
    Expression quantitative trait loci for TNFRSF10 influence both HBV infection and hepatocellular carcinoma development.
    J Med Virol. 2016;88:474-80.
    PubMed     Text format     Abstract available


  141. AKHTAR A, Khan AH, Sulaiman SA, Soo CT, et al
    HBV and HIV co-infection: Prevalence and clinical outcomes in tertiary care hospital Malaysia.
    J Med Virol. 2016;88:455-60.
    PubMed     Text format     Abstract available


    February 2016
  142. MAKHLOUF NA, Farghaly AM, Zaky S, Rashed HG, et al
    The efficacy of hepatitis B vaccination program in upper Egypt: Flow cytometry and the evaluation of long term immunogenicity.
    J Med Virol. 2016 Feb 22. doi: 10.1002/jmv.24506.
    PubMed     Text format     Abstract available


  143. LIU Y, Chen L, Zou Z, Zhu B, et al
    Hepatitis C virus infection induces elevation of CXCL10 in human brain microvascular endothelial cells.
    J Med Virol. 2016 Feb 19. doi: 10.1002/jmv.24504.
    PubMed     Text format     Abstract available


  144. AL-MUGHALES JA
    Co-infection assessment in HBV, HCV and HIV patients in western Saudi Arabia.
    J Med Virol. 2016 Feb 19. doi: 10.1002/jmv.24503.
    PubMed     Text format     Abstract available


  145. GEDEDZHA MP, Muzeze M, Burnett RJ, Amponsah-Dacosta E, et al
    Complete genome analysis of hepatitis B virus in human immunodeficiency virus infected and uninfected South Africans.
    J Med Virol. 2016 Feb 17. doi: 10.1002/jmv.24502.
    PubMed     Text format     Abstract available


  146. AROUCHA DC, Carmo RF, Vasconcelos LR, Lima RE, et al
    TNF-alpha and IL-10 polymorphisms increase the risk to hepatocellular carcinoma in HCV infected individuals.
    J Med Virol. 2016 Feb 17. doi: 10.1002/jmv.24501.
    PubMed     Text format     Abstract available


  147. LI M, Wang W, Jin R, Zhang T, et al
    Differential association of STAT3 and HK-II expression in hepatitis B virus- and hepatitis C virus-related hepatocellular carcinoma.
    J Med Virol. 2016 Feb 17. doi: 10.1002/jmv.24498.
    PubMed     Text format     Abstract available


  148. COSSABOOM CM, Heffron CL, Cao D, Yugo DM, et al
    Risk factors and sources of foodborne hepatitis E virus infection in the United States.
    J Med Virol. 2016 Feb 17. doi: 10.1002/jmv.24497.
    PubMed     Text format     Abstract available


  149. CHAUHAN R, Singh AK, Rooge S, Varshney A, et al
    Analysis of hepatitis B virus genotype changes in patients with chronic hepatitis B infection on tenofovir therapy.
    J Med Virol. 2016 Feb 9. doi: 10.1002/jmv.24489.
    PubMed     Text format     Abstract available


  150. BENSALEM A, Selmani K, Narjes H, Bencherifa N, et al
    Eastern region represents a worrying cluster of active hepatitis C in Algeria in 2012.
    J Med Virol. 2016 Feb 9. doi: 10.1002/jmv.24491.
    PubMed     Text format     Abstract available


    January 2016
  151. STEVENS K, Palmo T, Wangchuk T, Solomon S, et al
    Hepatitis B prevalence and treatment needs among Tibetan refugees residing in India.
    J Med Virol. 2016 Jan 29. doi: 10.1002/jmv.24488.
    PubMed     Text format     Abstract available


  152. D'ETTORRE G, Ceccarelli G, Serafino S, Giustini N, et al
    Dominant enrichment of phenotypically activated CD38 HLA-DR CD8 T cells, rather than CD38 HLA-DR CD4 T cells, in HIV/HCV coinfected patients on antiretroviral therapy.
    J Med Virol. 2016 Jan 14. doi: 10.1002/jmv.24475.
    PubMed     Text format     Abstract available


  153. BOKHARAEI-SALIM F, Keyvani H, Esghaei M, Zare-Karizi S, et al
    Prevalence of occult hepatitis C virus infection in the Iranian patients with human immunodeficiency virus infection.
    J Med Virol. 2016 Jan 14. doi: 10.1002/jmv.24474.
    PubMed     Text format     Abstract available


  154. TRIMBITAS RD, Fayssel N, Serghini FZ, Wakrim L, et al
    Molecular characterization of hepatitis C virus core region in Moroccan intravenous drug users.
    J Med Virol. 2016 Jan 11. doi: 10.1002/jmv.24470.
    PubMed     Text format     Abstract available


  155. ESMAT G, El Raziky M, Nabeel MM, Maher R, et al
    Seroprevalence of HCV among Cairo University students in Egypt.
    J Med Virol. 2016 Jan 11. doi: 10.1002/jmv.24469.
    PubMed     Text format     Abstract available


  156. WANG L, Zheng Y, Fu C, Huang S, et al
    Seroprevalence of hepatitis E virus infection among dogs in several developed cities in the Guangdong province of China.
    J Med Virol. 2016 Jan 7. doi: 10.1002/jmv.24468.
    PubMed     Text format     Abstract available


  157. ABDELRAHIM SS, Khiry RM, Esmail MA, Ragab M, et al
    Occult hepatitis C virus infection among Egyptian hemodialysis patients.
    J Med Virol. 2016 Jan 7. doi: 10.1002/jmv.24467.
    PubMed     Text format     Abstract available


  158. KATOONIZADEH A, Ghoroghi S, Sharafkhah M, Khoshnia M, et al
    Chronic hepatitis B infection is not associated with increased risk of vascular mortality while having an association with metabolic syndrome.
    J Med Virol. 2016 Jan 7. doi: 10.1002/jmv.24466.
    PubMed     Text format     Abstract available


  159. ARAIN A, Bourgeois S, de Galocsy C, Henrion J, et al
    Belgian experience with triple therapy with boceprevir and telaprevir in genotype 1 infected patients who inject drugs.
    J Med Virol. 2016;88:94-9.
    PubMed     Text format     Abstract available


  160. SUN HH, Zhou DF, Zhou JY
    The role of DCs in the immunopathogenesis of chronic HBV infection and the methods of inducing DCs maturation.
    J Med Virol. 2016;88:13-20.
    PubMed     Text format     Abstract available


    December 2015
  161. NDIAYE O, Gozlan J, Diop-Ndiaye H, Sall AS, et al
    Usefulness of Dried Blood Spots (DBS) to perform hepatitis C virus genotyping in drug users in Senegal.
    J Med Virol. 2015 Dec 24. doi: 10.1002/jmv.24460.
    PubMed     Text format     Abstract available


  162. LO G, Sow-Sall A, Diop-Ndiaye H, Mandiouba NC, et al
    Response to comments by Honge et al. on our paper titled "Prevalence of hepatitis B markers in Senegalese HIV-1 infected patients".
    J Med Virol. 2015 Dec 22. doi: 10.1002/jmv.24452.
    PubMed     Text format     Abstract available


  163. HONGE BL, Jespersen S, Medina C, Wejse C, et al
    Comment on Lo et al.: Prevalence of hepatitis B markers in Senegalese HIV-1 infected patients.
    J Med Virol. 2015 Dec 22. doi: 10.1002/jmv.24455.
    PubMed     Text format     Abstract available


  164. HUNDIE GB, Raj VS, Gebre Michael D, Pas SD, et al
    Molecular epidemiology and genetic diversity of hepatitis B virus in Ethiopia.
    J Med Virol. 2015 Dec 2. doi: 10.1002/jmv.24437.
    PubMed     Text format     Abstract available


    November 2015
  165. DE ARAUJO MARIZ C, Lopes EP, Ximenes RA, Lacerda HR, et al
    Serological markers of hepatitis B and C in patients with HIV/AIDS and active tuberculosis.
    J Med Virol. 2015 Nov 18. doi: 10.1002/jmv.24432.
    PubMed     Text format     Abstract available


    August 2015
  166. NIKOLOPOULOS GK, Paraskevis D, Psichogiou M, Hatzakis A, et al
    HBV-DNA levels predict overall mortality in HIV/HBV coinfected individuals.
    J Med Virol. 2015 Aug 19. doi: 10.1002/jmv.24357.
    PubMed     Text format     Abstract available


  167. LIU MH, Chen QY, Harrison TJ, Li GJ, et al
    The correlation between serum HBsAg levels and viral loads depends upon wild-type and mutated HBV sequences rather than the HBeAg/anti-HBe status.
    J Med Virol. 2015;87:1351-60.
    PubMed     Text format     Abstract available


    June 2015
  168. STROFFOLINI T, Esvan R, Biliotti E, Sagnelli E, et al
    Gender differences in chronic HBsAg carriers in Italy: Evidence for the independent role of male sex in severity of liver disease.
    J Med Virol. 2015 Jun 2. doi: 10.1002/jmv.24243.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: